Results 221 to 230 of about 12,151 (255)
Some of the next articles are maybe not open access.
Allergy, 2001
Cysteinyl leukotrienes, synthesized de novo from cell membrane phospholipids, are proinflammatory mediators that play an important role in the pathophysiology of asthma. These mediators are among the most potent of bronchoconstrictors and cause vasodilation, increased microvascular permeability, exudation of macromolecules and edema.
openaire +2 more sources
Cysteinyl leukotrienes, synthesized de novo from cell membrane phospholipids, are proinflammatory mediators that play an important role in the pathophysiology of asthma. These mediators are among the most potent of bronchoconstrictors and cause vasodilation, increased microvascular permeability, exudation of macromolecules and edema.
openaire +2 more sources
Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents
1991Arachidonic acid is converted by mammalian enzymes to a variety of oxygenated metabolites which include prostaglandins, thromboxanes and leukotrienes (collectively called eicosanoids). Many of these naturally occurring compounds have potent biological activities which suggest that they could be involved in mediating symptoms associated with various ...
J A, Salmon, L G, Garland
openaire +2 more sources
Leukotriene Receptor Antagonists in the Treatment of Asthma
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2001The role of leukotriene receptor antagonists in the treatment of persistent asthma is in evolution. Pivotal 8–12‐week, randomized, controlled trials in both adults and children have shown efficacy, as defined by standard asthma outcomes. Tolerance to therapy did not develop, nor did rebound worsening of asthma symptoms once therapy was withdrawn.
openaire +2 more sources
Role of Leukotrienes and Leukotriene Receptor Antagonists in Asthma
Pulmonary Pharmacology & Therapeutics, 1999T R, Jones, I W, Rodger
openaire +2 more sources
New and promising type of leukotriene B4 (LTB4) antagonists based on the 1,4-benzodioxine structure
European Journal of Medicinal Chemistry, 2023Latifa Bouissane +2 more
exaly